| 产品详情 |
| Edit |   |
|---|
| Product Name | SMT3 Suppressor of Mif Two 3 Homolog 2 (S. Cerevisiae) (SUMO2) protein (HA tag,AMCA) |
|---|
| Description | Small Ubiquitin-like Modifier 2 (SUMO2), also known as Sentrin2 and SMT3B is synthesized as a 95 amino acid (aa), propeptide with a predicted 11 kDa. SUMO2 contains a two aa C-terminal prosegment and an 18 aa N-terminal protein interacting region between aa 33-50. Human SUMO2 shares 100% aa sequence identity with mouse SUMO2. SUMO2 also has very high aa sequence identity with SUMO3 and SUMO4, 86% and 85%, respectively. SUMO2 shares only 44% aa sequence identity with SUMO1. SUMOs are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed SUMOylation. All SUMO proteins share a conserved ubiquitin domain and a C-terminal diglycine cleavage/attachment site. Following prosegment cleavage, the C-terminal glycine residue of SUMO2 is enzymatically attached to a lysine residue on a target protein. In humans, SUMO2 is conjugated to a variety of molecules in the presence of the SAE1/UBA2 SUMO-activating (E1) enzyme and the UBE2I/Ubc9 SUMO-conjugating (E2) enzyme. In yeast, the SUMO-activating (E1) enzyme is Aos1/Uba2p. Because of the high level of aa sequence identity most studies report effects of SUMO2/3. For example, post-translational addition of SUMO2/3 was shown to modulate the function of ARHGAP21, a RhoGAP protein known to be involved in cell migration. Other reports indicate that the SUMOylation with SUMO2/3, but not SUMO1, may represent an important mechanism to protect neurons during episodes of cerebral ischemia. However, studies suggest that SUMO2/3 expression is regulated in an isoform-specific manner since oxidative stress downregulated the transcription of SUMO3 but not SUMO2. SUMOylation can occur without the requirement of a specific E3 ligase activity, where SUMO is transferred directly from UbcH9 to specific substrates. SUMOylated substrates are primarily localized to the nucleus (RanGAP-1, RANBP2, PML, p53, Sp100, HIPK2), but there are also cytosolic substrates (IkappaBalpha, GLUT1, GLUT4). SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation, transcriptional regulation, cancer and protein stability. |
|---|
| Size | 50 µg |
|---|
| Concentration | n/a |
|---|
| Applications | SDS-PAGE (SDS) |
|---|
| Other Names | SUMO2|HSMT3|SMT3B|SMT3H2|SUMO3|Smt3A|Smt3h2|hsmt3|smt3b|smt3h2|sumo-2|sumo2|SMT3A|SMT3H1|SUMO-3|Smt3B|ATSUMO2|MCO15.11|MCO15_11|SMALL UBIQUITIN-LIKE MODIFIER 2|SUM2|SUMO 2|small ubiquitin-like modifier 2|PSMT3|SUMO-2|Smt3b|zgc:92241 |
|---|
| Gene, Accession, CAS # | Gene ID: 6613 |
|---|
| Catalog # | ABIN2745849 |
|---|
| Price | |
|---|
| Order / More Info | SMT3 Suppressor of Mif Two 3 Homolog 2 (S. Cerevisiae) (SUMO2) protein (HA tag,AMCA) from ANTIBODIES-ONLINE GmbH |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|